RT Journal Article
SR Electronic
T1 Rapid and Sensitive Detection of SARS-CoV-2 Infection Using Quantitative Peptide Enrichment LC-MS Analysis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.02.21258097
DO 10.1101/2021.06.02.21258097
A1 Hober, Andreas
A1 Hua, Tran-Minh Khue
A1 Foley, Dominic
A1 McDonald, Thomas
A1 Vissers, Johannes P.C.
A1 Pattison, Rebecca
A1 Ferries, Samantha
A1 Hermansson, Sigurd
A1 Betner, Ingvar
A1 Uhlen, Mathias
A1 Razavi, Morteza
A1 Yip, Richard
A1 Pope, Matthew E.
A1 Pearson, Terry W.
A1 Anderson, N. Leigh
A1 Bartlett, Amy
A1 Calton, Lisa
A1 Alm, Jessica J.
A1 Engstrand, Lars
A1 Edfors, Fredrik
YR 2021
UL http://medrxiv.org/content/early/2021/10/26/2021.06.02.21258097.abstract
AB Reliable, robust, large-scale molecular testing for SARS-CoV-2 is essential for monitoring the ongoing Covid-19 pandemic. We have developed a scalable analytical approach to detect viral proteins based on peptide immunoaffinity enrichment combined with liquid chromatography - mass spectrometry (LC-MS). This is a multiplexed strategy, based on targeted proteomics analysis and read-out by LC-MS, capable of precisely quantifying and confirming the presence of SARS-CoV-2 in PBS swab media from combined throat/nasopharynx/saliva samples.The results reveal that the levels of SARS-CoV-2 measured by LC-MS correlate well with their corresponding RT-PCR readout (r=0.79). The analytical workflow shows similar turnaround times as regular RT-PCR instrumentation with a quantitative readout of viral proteins corresponding to cycle thresholds (Ct) equivalents ranging from 21 to 34. Using RT-PCR as a reference, we demonstrate that the LC-MS-based method has 100% negative percent agreement (estimated specificity) and 95% positive percent agreement (estimated sensitivity) when analyzing clinical samples collected from asymptomatic individuals with a Ct within the limit of detection of the mass spectrometer (Ct ≤30). These results suggest that a scalable analytical method based on LC-MS has a place in future pandemic preparedness centers to complement current virus detection technologies.Competing Interest StatementThe authors declare the following competing financial interest(s): D.F, T.M, J.V, R.P, S.F, I.B, S.H, A.B, L.C are employed by Waters Corporation. M.R, R.Y, M.E.P, T.W.P and N.L.A are employed by SISCAPA Assay Technologies.Clinical TrialDNR - 2020-06395Funding StatementNo external funding was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Regional ethics board ni Linkoping, SwedenI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe proteomics data have been deposited to Panorama Public [38] (https://panoramaweb.org/sars-cov-2_siscapa.url; login: panoramareviewer{at}gmail.com, pwd: scilifelab), allowing for access to raw files and integrated peak areas from as well as visualization of LC-MRM/MS chromatograms. https://panoramaweb.org/sars-cov-2_siscapa.url